Psilocybin clinical trials in New Mexico
2 trials with 3 study sites in New Mexico, recruiting or not yet recruiting, read from ClinicalTrials.gov on 28 October 2026. The site in New Mexico is named under each trial.
- RecruitingPhase 2NCT06796062
Psilocybin for Opioid Use Disorder (OUD)
Opioid Use Disorder · NYU Langone Health · Ages 18 to 65
5 sites in United States
In New Mexico: Duke City Recovery Toolbox, Albuquerque; University of New Mexico, Albuquerque
- RecruitingPhase 1NCT07506395
Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder
PTSD · University of New Mexico · Ages 18 to 89
Albuquerque, New Mexico, United States
In New Mexico: Interdisciplinary Substance Use and Brain Injury (ISUBI), Albuquerque
How joining a trial works
- Free to take part
- Trials generally cost participants nothing for the study drug and the study visits, and some pay for travel or time. Check what a study covers on its registry page.
- Screened first
- Every study screens volunteers with questionnaires, medical history and often a physical and psychiatric check. Many people who apply are not enrolled.
- Eligibility is strict
- Common exclusions include a personal or family history of psychosis or bipolar disorder, some heart conditions, pregnancy and certain medications, which you may be asked to stop under medical supervision. Never stop a medication on your own to qualify.
- You may get a placebo
- Many trials compare psilocybin with a placebo or a low dose, and you may not be told which you had until the study ends.
- Contact the study team through the registry
- Each registry record lists the study contacts and sites. We do not republish personal emails or phone numbers; use the link on each trial page.
- Not medical advice
- This is a list of registry records, not a recommendation. Talk to your doctor before applying. Disclaimer · Safety and medications
Source: ClinicalTrials.gov API v2, U.S. National Library of Medicine, read 28 October 2026. Filter: overall status RECRUITING or NOT_YET_RECRUITING; an intervention named psilocybin, psilocin, COMP360 or CYB003. Refreshed weekly; a study's own registry page is always the current record.